Posted By:
Kelly Parcell
Category:
Integrative Cancer Support
Kelly Parcell, ND So far, all studies examining the effects of hormone replacement therapy have shown no major reduction of cardiovascular risk. In fact, equine estrogens (Premarin) and progestins (Provera) appear to be associated with increased cardiovascular risk. Naturally occurring estrogen does not fully account for why women get heart disease later than men either. According to a BMJ study in 1995 of postmenopausal women, there was no relationship between estrogens—or any other measured sex steroid—to CAD risk. These results were consistent with those from previous studies that found no difference in estrogen levels in women with or without CAD.A trial by the Women’s Health Initiative (WHI) failed to show decreased risk of heart attack in women despite improvement in lipid levels. Estrogen can lower Lip (a) as well. However, only non-bioidentical, horse-derived estrogen and synthetic progesterone were used. The WHI trial also did not demonstrate any overall benefit of estrogen alone (versus a placebo) for decreasing mortality caused by CAD, although there was a good suggestion of benefit in the 50- to 59-year-old group. Other recent studies have also failed to demonstrate the benefits of hormone replacement on CAD risk, coronary calcification, progression of carotid intima-medial wall thickness, and...